Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids.

•Comparison of drisapersen-treated with untreated matched natural history subjects.•Matching was performed by baseline age (±6 mo) and 6MWD (±30 m) as primary analysis.•Matching was performed by baseline age and RFF (±0.5 s) as sensitivity analysis.•Over up to 3.4 years, a difference in favour of drisapersen was seen for 6MWD and RFF.